Literature DB >> 8474934

Drug-drug interactions with fluoroquinolones.

C R Marchbanks1.   

Abstract

Antimicrobials of the fluoroquinolone class are involved in a number of clinically important drug-drug interactions. Many of these interactions occur with all the available agents and exhibit little interpatient variability. In contrast, others occur only with specific fluoroquinolones and their extent varies markedly among subjects. The oral absorption of all fluoroquinolones is significantly impaired when coadministered with aluminum- and magnesium-containing antacids and sucralfate, as well as with other metal cations such as calcium and iron. Concomitant use of these agents, even when dosed several hours apart, should be avoided. Enoxacin and ciprofloxacin impair the hepatic metabolism of theophylline and caffeine, leading to significantly increased serum concentrations. Ofloxacin and lomefloxacin have only minimal effects on xanthine metabolism. Case reports suggest that concomitant administration of several fluoroquinolones and warfarin, a drug that is also highly metabolized by the liver, leads to increased hypoprothrombinemic effects; prospective studies, however, failed to confirm this interaction. Clinicians must be aware of these and other potential drug-drug interactions with fluoroquinolones for optimal use of the agents.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8474934

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  14 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.

Authors:  H Stass; U Schühly; J G Möller; H Delesen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Comparative dispositions of ofloxacin in human head, axillary, and pubic hairs.

Authors:  K Kosuge; T Uematsu; S I Araki; H Matsuno; K Ohashi; M Nakashima
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

4.  Pharmacokinetic evaluation of oral levofloxacin in human immunodeficiency virus-infected subjects receiving concomitant antiretroviral therapy.

Authors:  P Villani; P Viale; L Signorini; B Cadeo; F Marchetti; A Villani; C Fiocchi; M B Regazzi; G Carosi
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

5.  The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple dose caffeine.

Authors:  D P Nicolau; C H Nightingale; P R Tessier; Q Fu; D W Xuan; E M Esguerra; R Quintiliani
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 6.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

Review 7.  A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.

Authors:  S J Martin; R Jung; C G Garvin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

8.  Inflammatory bowel disease of the elderly: a wake-up call.

Authors:  Seymour Katz; Richard Feldstein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-05

Review 9.  Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.

Authors:  R Davis; H M Bryson
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

10.  Anticoagulant-induced changes on antibiotic concentrations in the serum and bones.

Authors:  A Kotsiou; E Diamanti; A Potamianou; H Parara; J Vovou; C Perisanidis; C Tes; C Tesseromatis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Jul-Sep       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.